Today: 10 June 2026
BigBear.ai stock in focus before the open as Jan. 16 note redemption nears after CPI
13 January 2026
1 min read

BigBear.ai stock in focus before the open as Jan. 16 note redemption nears after CPI

New York, Jan 13, 2026, 08:54 EST — Premarket

  • BigBear.ai shares hovered close to Monday’s finish, with traders holding back after a volatile run.
  • Focus turns to the Jan. 16 redemption of the company’s 6% convertible notes maturing in 2029.
  • Investors are weighing new U.S. inflation figures and their potential impact on rate cuts.

Shares of BigBear.ai Holdings edged slightly lower in premarket trading Tuesday, following a 1.77% gain to $6.31 in the previous session.

Attention turns to the coming days as the small-cap defense AI company faces a Jan. 16 redemption deadline on its 6.00% convertible senior secured notes due 2029 — bonds that can convert into shares. A regulatory filing detailed the terms, highlighting a boosted share conversion rate for notes converted in early January.

Investors digested the December U.S. Consumer Price Index data, with prices climbing 0.3% month-over-month and 2.7% year-over-year, according to the Labor Department. Core inflation, which strips out food and energy, ticked up 0.2% for the month and 2.6% over the past year.

BigBear.ai announced earlier this month plans to slash roughly $125 million in debt via a combination of voluntary conversions and cash redemptions for any notes not converted by the deadline. The company aims to issue around 38 million shares to cover conversions. CEO Kevin McAleenan described the move as “an important step” toward bolstering the balance sheet. BigBear.ai Holdings, Inc.

For a company of its scale, the stock saw notably heavy volume. On Monday, shares fluctuated between $6.06 and $6.35, with roughly 62.9 million shares traded, according to Nasdaq data.

Convertible notes can lower borrowing costs, yet they risk diluting shareholders if the debt turns into equity. This trade-off is front and center again: reduced interest expenses and lighter leverage come at the cost of adding more shares to the market.

There’s a catch. Noteholders aren’t obligated to convert, which means the company must pay cash to redeem any notes left unconverted by the deadline. Plus, if holders decide to sell the shares they get, the increased float could put pressure on the stock.

Investors should note a key date on the calendar: BigBear.ai’s investor site shows a special stockholders meeting scheduled to reconvene on Jan. 22 at 3:00 p.m. EST.

Traders have viewed smaller AI names as rate-sensitive plays, with price swings often magnified by movements in bond yields and shifts in risk appetite—beyond just the company’s own capital-structure moves. Defense-oriented analytics firms like Palantir also navigate this tricky mix of government spending forecasts and fluctuating market multiples.

Stock Market Today

  • Palantir Technologies (PLTR) Shares Seen Fairly Valued Amid Recent Decline
    June 10, 2026, 5:48 PM EDT. Palantir Technologies has seen its share price fall 13.2% over the past week and 21.3% year to date, following extraordinary gains in prior years. At $132.07 per share, Palantir trades slightly below its estimated intrinsic value of $145.11 based on a Discounted Cash Flow (DCF) analysis, suggesting a modest 9% discount. The company posted $2.69 billion in free cash flow over the past twelve months, with projections rising to $16.11 billion by 2030. Despite recent volatility tied to sentiment on artificial intelligence and software spending, Palantir remains fairly valued but not a clear bargain. Investors should monitor further market developments and valuation metrics to gauge future opportunities or risks.

Latest articles

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

10 June 2026
Parabilis Medicines soared 58% above its $20 IPO price to close at $31.60 in its Nasdaq debut after raising a record $670 million, reflecting strong investor demand for its Helicon drug platform ahead of a pivotal Phase 3 desmoid tumor trial planned for 2027; Regeneron’s $75 million private placement added credibility.
Joby Aviation Shares Slip After CFO Files to Sell Stock

Joby Aviation Shares Slip After CFO Files to Sell Stock

10 June 2026
Joby Aviation fell 4.47% to $8.86 after CFO Rodrigo Brumana disclosed selling 78,489 shares under a prearranged 10b5-1 plan, with no new certification or commercial-launch updates, leaving investors focused on regulatory progress and cash burn as the key catalysts for the stock.
YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
ZIM stock edges up in premarket after a 52-week high run — what traders watch next
Previous Story

ZIM stock edges up in premarket after a 52-week high run — what traders watch next

Dow Jones today: DJIA slips from record as Visa and banks weigh after CPI
Next Story

Dow Jones today: DJIA slips from record as Visa and banks weigh after CPI

Go toTop